Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SON-1010
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Sonnet BioTherapeutics
Deal Size : $5.0 million
Deal Type : Public Offering
Sonnet Prices $5M Public Offering At Market Under Nasdaq Rules
Details : Sonnet will use the net proceeds for research and development, including SON-1010, a candidate immunotherapeutic recombinant drug, targeting solid tumors.
Brand Name : SON-1010
Molecule Type : Large molecule
Upfront Cash : Undisclosed
November 06, 2024
Lead Product(s) : SON-1010
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Sonnet BioTherapeutics
Deal Size : $5.0 million
Deal Type : Public Offering
LOOKING FOR A SUPPLIER?